


PHARMACEUTICAL 2022

IMMUNIC INC. Rank 363 of 475





PHARMACEUTICAL 2022

IMMUNIC INC. Rank 363 of 475

The relative strengths and weaknesses of IMMUNIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUNIC INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 98% points. The greatest weakness of IMMUNIC INC. is the variable Net Income, reducing the Economic Capital Ratio by 215% points.

The company's Economic Capital Ratio, given in the ranking table, is -304%, being 28% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	104,988
Cost of Goods Sold	0
Intangible Assets	32,970
Liabilities, Current	11,401
Liabilities, Non-Current	584
Other Assets	990
Other Compr. Net Income	3,860
Other Expenses	17,250
Other Liabilities	0
Other Net Income	-1,280
Property and Equipment	152
Research and Development	61,115
Revenues	0
Selling, General and Administrative Expense	13,300

Output Variable	Value in 1000 USD
Assets	139,100
Liabilities	11,985
Expenses	91,665
Stockholders Equity	127,115
Net Income	-92,945
Comprehensive Net Income	-91,015
Economic Capital Ratio	-304%